Tanios S. Bekaii-Saab

Oncology

5777 E Mayo Blvd
Phoenix, AZ 85054

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 421 publications

Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers.

Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers.

Journal: JCO precision oncology

Published: July 10, 2026

Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers.

Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers.

Journal: JCO precision oncology

Published: July 10, 2026

Phase 2 Study of Futibatinib in Combination with Pembrolizumab in Patients with FGF19 expressing Advanced Hepatocellular Carcinoma.

Phase 2 Study of Futibatinib in Combination with Pembrolizumab in Patients with FGF19 expressing Advanced Hepatocellular Carcinoma.

Journal: The oncologist

Published: June 11, 2026

Digitally enriching a screening population for pancreatic cancer using routine blood-based measures and clinical histories.

Digitally enriching a screening population for pancreatic cancer using routine blood-based measures and clinical histories.

Journal: ArXiv

Published: June 05, 2026

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 01, 2026

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial.

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 01, 2026

Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study.

Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study.

Journal: Journal of gastrointestinal oncology

Published: May 25, 2026

Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.

Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.

Journal: ESMO gastrointestinal oncology

Published: May 22, 2026

Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial'.

Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial'.

Journal: ESMO open

Published: May 22, 2026

Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience.

Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience.

Journal: JCO precision oncology

Published: April 09, 2026

Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer.

Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer.

Journal: JCO precision oncology

Published: April 03, 2026

Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal Carcinoma.

Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal Carcinoma.

Journal: JCO precision oncology

Published: March 25, 2026

Showing 1-12 of 421

Last Updated: 09/26/2026